New cholesterol drug tested in liver patients
NCT ID NCT06575959
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 study looked at how the experimental cholesterol-lowering drug enlicitide is processed in the body of people with mild or moderate liver impairment compared to healthy volunteers. Twenty participants received a single oral dose, and researchers measured drug levels in the blood over time. The goal is to understand if liver problems affect how the drug is handled, which could guide future dosing recommendations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
enlicitide (oral tablet)
What this could lead to
If successful, this study could help doctors determine the right dose of enlicitide for people with liver problems, making the drug safer and more effective.
What could go wrong
This is a very early, small study (20 people) focused on drug levels, not on whether enlicitide actually lowers cholesterol or improves health. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Orlando Clinical Research Center ( Site 0002)
Orlando, Florida, 32809, United States
-
The Texas Liver Institute ( Site 0001)
San Antonio, Texas, 78215, United States